Mohammad Jafferany, MD
Child & Adolescent Psychiatry · Saginaw, MINPI 1811008139
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,270 of the $10,012 with a category attached, or 62.6%. 22 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 48.8% of the total. Among child & adolescent psychiatry clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $53.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$5K
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$476
- Lundbeck LLC$333
- Takeda Pharmaceuticals U.S.A., Inc.$295
- Neurocrine Biosciences, Inc.$190
- plus $1K from 16 others
Across 2 payments — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$7K
What the payments were for
- Speaking & faculty fees$6,27063%
- Travel & lodging$1,08611%
- Food & beverage$2,64026%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 2 | $4,887 |
| AbbVie(2 entities) | 26 | $2,718 |
| Otsuka America Pharmaceutical, Inc. | 33 | $476 |
| Lundbeck LLC | 21 | $333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $295 |
| Neurocrine Biosciences, Inc. | 12 | $190 |
| Supernus Pharmaceuticals, Inc. | 10 | $182 |
| Johnson & Johnson | 12 | $178 |
| Sunovion Pharmaceuticals Inc. | 12 | $151 |
| Shire North American Group Inc | 7 | $124 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Ironshore Pharmaceuticals Inc. | 7 | $113 |
| Vertical Pharmaceuticals, LLC | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Tris Pharma Inc | 2 | $30 |
| OWP Pharmaceuticals, Inc. | 2 | $26 |
| Alkermes, Inc. | 1 | $21 |
| Validus Pharmaceuticals LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,400
How this compares
$10,012 in reported general payments places this provider in the 90th percentile of 73 child & adolescent psychiatry providers in Michigan.
See all child & adolescent psychiatry providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risperdal ConstaRisperidone Microspheres | 17 | $10,825 |
| Aripiprazole | 48 | $2,241 |
| Buspirone Hcl | 70 | $885 |
| Oxcarbazepine | 14 | $881 |
| Lamotrigine | 46 | $814 |
| Bupropion XlBupropion Hcl | 30 | $664 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $533 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $478 |
| Duloxetine Hcl | 21 | $457 |
| Clonazepam | 72 | $373 |
| Escitalopram Oxalate | 26 | $349 |
| Trazodone Hcl | 33 | $305 |
| Quetiapine Fumarate | 23 | $247 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $197 |
| Alprazolam | 45 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal Consta | $178 | $10,82517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 child & adolescent psychiatry providers in Michigan.
Other child & adolescent psychiatry in Saginaw
- Shailja PandyaSaginaw$61
- Luis RodriguezSaginaw$23
- Birgit AmannTroy$980K
- David VillanuevaSterling Heights$140K
- Carol Crouch-RossLivonia$24K
- Robert GarciaNorthville$24K
- Gerald SchmukerSpring Lake$11K
- Sridevi KodaliLivonia$7K
- Viken MatossianHowell$5K
- Seema KumarWest Bloomfield$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.